Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.24.3
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
OPERATING REVENUE:        
TOTAL OPERATING REVENUE $ 362,124 $ 288,351 $ 1,129,769 $ 919,514
OPERATING EXPENSE:        
Medical expense 401,920 279,220 1,149,148 867,061
Premium deficiency reserve 18,168 (12,489) 15,771 (9,361)
Corporate, general and administrative expense 27,219 33,065 81,230 97,931
Sales and marketing expense 134 654 870 2,512
Depreciation and amortization 21,673 21,721 64,905 65,041
TOTAL OPERATING EXPENSE 469,114 322,171 1,311,924 1,023,184
OPERATING LOSS (106,990) (33,820) (182,155) (103,670)
OTHER INCOME (EXPENSE):        
Interest expense, net (5,647) (4,002) (15,339) (11,939)
Mark-to-market of stock warrants 5,737 755 14,626 (327)
Other 445 190 1,073 (455)
TOTAL OTHER INCOME (EXPENSE) 535 (3,057) 360 (12,721)
LOSS BEFORE INCOME TAXES (106,455) (36,877) (181,795) (116,391)
INCOME TAX BENEFIT (PROVISION) 3,605 (412) 565 (928)
NET LOSS (102,850) (37,289) (181,230) (117,319)
LESS: NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING INTEREST (56,338) (23,993) (103,998) (85,008)
NET LOSS ATTRIBUTABLE TO CONTROLLING INTEREST $ (46,512) $ (13,296) $ (77,232) $ (32,311)
NET LOSS PER SHARE (Note 9):        
Basic (in dollars per share) $ (0.29) $ (0.12) $ (0.55) $ (0.37)
Diluted (in dollars per share) $ (0.31) $ (0.12) $ (0.64) $ (0.41)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (Note 9):        
Basic (in shares) 161,890 114,198 139,292 88,010
Diluted (in shares) 164,701 312,679 141,723 288,379
Capitated Revenue [Member]        
OPERATING REVENUE:        
TOTAL OPERATING REVENUE $ 357,706 $ 285,153 $ 1,116,146 $ 909,473
Other patient service revenue        
OPERATING REVENUE:        
TOTAL OPERATING REVENUE $ 4,418 $ 3,198 $ 13,623 $ 10,041